Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Photobiomodulation: Preventing and treating certain side effects of cancer treatments
A valuable asset in oncology, photobiomodulation or low-energy laser/LED therapy is used for its analgesic, anti-inflammatory, and healing properties.
Published on
A valuable asset in oncology, photobiomodulation or low-energy laser/LED therapy is used for its analgesic, anti-inflammatory, and healing properties. An innovative, non-invasive, and painless technique that promotes tolerance to chemotherapy and radiotherapy treatments.
Gustave Roussy has just acquired its fourth photobiomodulation device. The technique involves exposing cells or tissues to specific wavelengths of light to stimulate their activity.
Numerous indications in oncological supportive care
In oncology, photobiomodulation is used to help heal damaged tissues, improve immune response, reduce inflammation, and prevent or treat certain side effects of treatments such as chemotherapy and radiotherapy. Recommended for the prevention of mucositis (inflammation of the oral mucosa) and radiodermatitis (skin burns induced by radiotherapy), photobiomodulation is also the subject of recent clinical studies to expand its indications (peripheral neuropathies induced by certain chemotherapies, skin fibrosis, lymphedema, dry mouth or trismus). The technique is currently booming thanks to recent discoveries about its cellular mechanisms of action and progress in the setting of new devices. This non-invasive method with no identified side effects to date has yielded proven clinical results in indications that have not benefited from any other therapeutic alternative.
Last news
-
Breast Cancer: Gustave Roussy Ranked No. 1 in France for Breast Surgery and Breast Reconstruction
On the occasion of Breast Cancer Awareness Month, the 2025 data from Visuchir, the national surgical activity monitoring tool of the French Health Insurance system, places Gustave Roussy in first position for both breast surgery and breast reconstruction. Beyond this ranking, these figures highlight that reconstruction is now an integral part of breast cancer treatment. It is considered at every stage of care: from tumor removal surgery, whether lumpectomy or mastectomy, through to the post-cancer period, helping to restore the body and support women in regaining their physical integrity and quality of life.
-
Newsweek Ranking: Gustave Roussy Named Europe’s Leading Cancer Centre and Third Best Worldwide
The 2027 edition of Newsweek’s World's Best Specialized Hospitals ranking once again recognises Gustave Roussy as the leading cancer centre in France and Europe, and the third best worldwide. This distinction highlights the excellence of the Institute’s care and research, as well as the daily commitment of all its professionals.
-
Living with and beyond cancer: the promises and challenges of digital health
In a Viewpoint article published in The Lancet Digital Health, Drs Ines Vaz-Luis and Maria Alice Franzoi, together with Emmanuel Mussault, a patient partner at the PRISM University Hospital Institute, examine the role that digital tools can play in supporting people living with and beyond cancer. Their central message is that these technologies can support more personalised and accessible care, but their value depends primarily on how they are integrated into care pathways, the human support provided, their ability to address individual needs and their evaluation in real-world settings.
-
Gustave Roussy and The Lancet launch an international lecture series on innovations transforming cancer care
The inaugural lecture in the “Lecture Series on Cancer Breakthroughs” will take place on Friday 18 September at 5:00 pm. It will be delivered by Professor Timothy R. Rebbeck, a leading cancer prevention specialist at Harvard University and the Dana-Farber Cancer Institute.
